KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Raw Materials: 2010-2018

Historic Raw Materials for Teva Pharmaceutical Industries (TEVA) over the last 1 years, with Dec 2018 value amounting to $1.3 billion.

  • Teva Pharmaceutical Industries' Raw Materials fell 8.67% to $1.3 billion in Q4 2018 from the same period last year, while for Dec 2018 it was $1.3 billion, marking a year-over-year decrease of 8.67%. This contributed to the annual value of $1.3 billion for FY2018, which is 8.67% down from last year.
  • Teva Pharmaceutical Industries' Raw Materials amounted to $1.3 billion in Q4 2018, which was down 4.80% from $1.4 billion recorded in Q3 2018.
  • Teva Pharmaceutical Industries' 5-year Raw Materials high stood at $1.5 billion for Q1 2018, and its period low was $1.2 billion during Q4 2015.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Raw Materials value was $1.4 billion (recorded in 2018), while the average stood at $1.4 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Raw Materials dropped by 18.85% in 2014 and then increased by 15.90% in 2016.
  • Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Raw Materials stood at $1.3 billion in 2014, then decreased by 6.57% to $1.2 billion in 2015, then climbed by 15.90% to $1.4 billion in 2016, then grew by 4.98% to $1.5 billion in 2017, then declined by 8.67% to $1.3 billion in 2018.
  • Its Raw Materials stands at $1.3 billion for Q4 2018, versus $1.4 billion for Q3 2018 and $1.4 billion for Q2 2018.